Airway Disease Treatment Market

Airway Disease Treatment Market Outlook (2022 to 2032)

The global airway disease treatment market is expected to generate USD 3,495.3 Million in revenue by 2032, up from USD 1,996.1 Million in 2022, with a CAGR of 5.2% over the forecast period.

The steady growth in the market is owing to:

• An increase in focus on smart or digital inhalers for administering medications for COPD or asthma.
• Combination therapies are more often used since they are more efficient than using a bronchodilator and a corticosteroid separately. In addition, more individuals are now being effectively treated with combination treatment.
• The use of combination medications for airway disease treatment including asthma and COPD has received regulatory approval from organizations like the FDA, the European Commission, and the Ministry of Health, Labor, and Welfare (MHLW).
• The expanding population is a key contributor to the increase in air pollutants, which harm human health and causes a variety of respiratory illnesses.

Report Attribute	Details
Airway Disease Treatment Market Value (2022)	USD 1,996.1 Million
Airway Disease Treatment Market Anticipated Forecast Value (2032)	USD 3,495.3 Million
Airway Disease Treatment Market Projected Growth Rate (2022 to 2032)	5.2%

China and Japan to Dominate Asia Pacific Airway Disease Treatment Market

During the projection period, the Asia Pacific market is expected to grow at a faster rate. The growing presence of major products in the region is expected to fuel demand for asthma medications between 2022 and 2032.

Due to the existence of major players, China and Japan are projected to provide considerable potential in the market. For example, the rise of Pulmicort, a crucial asthma medicine, in the area has been driven by a favorable performance in China.

This factor, together with the availability of a huge and underserved market in the region, is expected to fuel market expansion in the Asia Pacific throughout the projection period. The rest of the international market, which includes Latin America, the Middle East, and Africa, is still in its infancy.

However, it is anticipated that throughout the projection period, rising chronic respiratory illness incidence and rising product introductions, especially effective generic asthma treatments, are likely to drive demand for airway disease treatments.

Globally, growing nations are opening up significant potential in the market for the treatment of respiratory disorders due to the high incidence of respiratory illnesses, increased accessibility to high-quality healthcare services, and expansion of the pharmaceutical sector.

The market for airway disease treatment has numerous growth opportunities due to the quick uptake of new technology and a surge in innovation.

Opportunities and Challenges for Airway Disease Treatment Market Players

During the drug development phase, pharmaceutical companies devote a significant amount of both monetary and non-monetary resources. The companies are completely in charge of the drug's manufacture and manufacturing while they have the patents for it.

The original pharmaceutical producer suffers significant losses as a result of generic drug manufacturers using the formula to produce their versions of the medications, which poses a difficult situation for the expansion of the global market.

As these businesses are positioned to acquire market share throughout the forecast period through the increased sales of their product offerings, this is anticipated to have a favorable influence on the airway disease treatment market growth.

Competition Analysis of Airway Disease Treatment Market

The market's competitive landscape shows a monopoly market structure with a large number of enterprises present. Due to the strength of their products in terms of asthma medications, two companies, AstraZeneca and GlaxoSmithKline dominated this industry.

The most notable products for GlaxoSmithKline were Advair and Flovent HFA/Flovent Diskus. These are the key elements that have contributed significantly to these firms' leading market positions. However, there are other well-known market participants, like Merck and Teva, which have sizable market revenue shares in the international market.

A generic asthma medication called fluticasone propionate and salmeterol inhalation powder, which is intended for the treatment of both asthma and chronic obstructive pulmonary disease, has completed phase III clinical research, according to Cipla Inc. (COPD). This potential possibility is the 100/50 mcg generic version of Advair Diskus.

Among the medications used in combination therapy for COPD are LABA-ICS, LAMA-ICS, triple therapy, and other similar drugs. Due to its superior efficacy over using a bronchodilator and a corticosteroid separately, combination therapy is becoming more popular, propelling the demand for airway disease treatment.

The airway disease treatment market growth is likely to augment owing to a rise in the number of patients who are successfully treated with combination therapy but who were not responding to bronchodilators or corticosteroid treatments. In addition, the adoption of airway disease treatment soars as the symptoms and quality of life of patients with chronic obstructive pulmonary disease can be improved more successfully with combination therapy than with monotherapy.

Combination therapy has also gained traction on account of recent regulatory approvals and a rise in the success rate of the treatment for COPD, aiding the overall market. Furthermore, the development of cutting-edge therapeutics for asthma by major market players is one of the critical factors holding sway over the airway disease treatment market trends and forecasts.

The adoption of airway disease treatment is facilitated by market characteristics such as solid and robust Research and Development efforts. One of the significant airway disease treatment market trends is the involvement of well-known pharmaceutical companies in the development of asthma medications, as asthma is a chronic disease that affects a sizable number of patients worldwide.

As part of this involvement, several promising asthma treatment candidates are currently undergoing various stages of clinical trials, influencing airway disease treatment adoption trends. For instance, in September 2019, Novartis released encouraging data from the phase III IRIDIUM study of the inhaled combination QVM149 in patients with uncontrolled asthma.

What Are The Key Airway Disease Treatment Market Dynamics?

On account of the rising prevalence of respiratory diseases such as asthma, cystic fibrosis, and COPD across the world, the demand for airway disease treatment is expected to skyrocket to a considerable extent. And the same can be primarily owed to the highly susceptible elderly people to respiratory diseases (COPD, asthma, emphysema) due to reduced immunity and blood flow.

Furthermore, the airway disease treatment market's key trends & opportunities are shaped by the introduction of advanced imaging technologies such as digital radiography and computed radiography as they render high-quality digital images.

Digital imaging systems have witnessed a low adoption rate as these are more expensive than analog imaging systems, dwindling the overall airway disease treatment market size during the forecast period. Since the pandemic and asthma are closely related to respiratory illnesses, there is an increased need for various types of asthma treatment medications, in turn, spiking the demand for airway disease treatment.

Due to rising demand and adoption of airway disease treatment, the USA FDA has granted priority regulatory approvals to several asthma medications, including important generic alternatives.

A key generic asthma treatment drug from Cipla, for example, received regulatory approval from the USA FDA in April 2020. Lupin is also expected to receive regulatory approval for a generic version of the same medication, auguring well for the airway disease treatment market's future trends.

The market is also positively impacted by the surging release of products with significant capability from well-known companies as a result of such developments and trends. Further efforts are made to prevent significant shortages of asthma medications by launching an increasing number of products.

Why Is North America Likely To Lead The Airway Disease Treatment Market?

Geographically, North America is anticipated to hold a major chunk of the airway disease treatment market share accounting for 38.1% in 2022.

The dominance of North America can be attributed to the rising incidence of respiratory diseases, the popularity of portable electronics, and the rising need for equipment and services for in-home medical care.

According to the American Lung Association, COPD is the third most common cause of death in the country. Additionally, a growing need for cutting-edge and inventive products in medical facilities, diagnostic labs, and outpatient ambulatory surgery centers would drive market expansion in the region.

What Is The Growth Outlook For The Airway Disease Treatment Market?

Europe holds second place in the market for treatments for airway disease, projected to dominate a market share of 22.5% in 2022.

The region's market is being driven by a well-established healthcare system and an increase in the prevalence of chronic obstructive pulmonary disease and Asthma is the most common issue among children.

A number of technological advancements in respiratory diagnostic testing have paved the way for the market's expansion, including the use of artificial intelligence and the Internet of things (IoT), among other things.

How Is The Start-up Ecosystem In The Airway Disease Treatment Market?

A US-based start-up, Altavant Sciences, is advancing therapies for managing rare respiratory diseases. The company's lead drug candidate, rodaristat ethyl, is a small molecule inhibitor of tryptophan hydroxylase (TPH).

The medication reduces serotonin levels in conditions like PAH and idiopathic pulmonary fibrosis (IPF). The start-up is also working on medicines to treat bronchiolitis obliterans syndrome. Exvastat, a British start-up, creates a drug that is modified to treat acute respiratory distress syndrome (ARDS).

Imatinib, a medication used to treat chronic myeloid leukemia, is being reformulated by the start-up. The newly developed medication makes use of its capacity to obstruct vascular leak, a cause of pulmonary edema.

How Strong Is The Competition In The Airway Disease Treatment Market?

Currently, the global airway disease treatment market is highly competitive owing to the involvement of many established players.

Some of the key players in the global airway disease treatment market are Holaira, Inc., VIDA Diagnostics, Boehringer Ingelheim International GmBH, AstraZeneca, Teva Pharmaceuticals, GlaxoSmithKline and Novartis.

Some of the recent developments in the airway disease treatment market are:

• Tudorza, also known as Eklira, and Duaklir distribution rights were sold by AstraZeneca for USD 270 million to the Swiss pharmaceutical company Covis Pharma Group.

These medications are intended to treat chronic obstructive pulmonary disease (COPD).

• The generic albuterol inhaler made by Cipla received regulatory approval from the USA FDA in response to the COVID-19 crisis-related shortages of asthma medications.

For people with asthma, this drug is frequently regarded as a last resort.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.2% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2016 to 2021
Forecast Period	2022 to 2032
Quantitative Units	Revenue in USD Million and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Type, Treatment, End Use, Region
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Japan; The Middle East and Africa
Key Countries Profiled	United States of America, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC Countries, South Africa
Key Companies Profiled	Holaira, Inc.; VIDA Diagnostics; Boehringer Ingelheim International GmBH; AstraZeneca; Teva Pharmaceuticals; GlaxoSmithKline; Novartis
Customization	Available Upon Request

Key Segments Profiled In The Airway Disease Treatment Market Survey

By Type:

• Asthma
• Chronic Obstructive Pulmonary Disorder
• Bronchiectasis

By Treatment:

• Bronchodilators
• Corticosteroids
• Cytotoxic Drugs
• Oxygen Therapy
• Antibiotics
• Others

By End Use:

• Hospitals
• Clinics
• ASCs
• Rehabilitation Centres
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Frequently Asked Questions

What is the Growth Outlook for the Airway Disease Treatment Market?

The global airway disease treatment market is set to advance at a CAGR of 5.2% (2022 to 2032).

What is the Projected North America Airway Disease Treatment Market Share?

North America is likely to hold an airway disease treatment market share of 38.1% in 2022.

What is the Future of Airway Disease Treatment Market?

The airway disease treatment market is predicted to account for USD 3,495.3 Million by 2032.